SlideShare une entreprise Scribd logo
1  sur  31
Télécharger pour lire hors ligne
BIOPHARMACEUTICAL
CLASSIFICATION SYSTEM
(BCS)
Presented By:-
Vaishnavi A. Bhosale
M.S. Pharmaceutics ( 1st Semester)
NIPER Hyderabad
1
CONTENTS:
• Introduction
• Objectives of BCS
• Factors affecting BCS Classification
• Classes of BCS
• Applications
• Bio wavers
• Limitations of BCS
• Extensions to BCS
• Conclusion
2
INTRODUCTION
• BCS is a scientific framework for classifying drugs based on
their AQUEOUS SOLUBILITY, INTESTINAL
PERMEABILITY and DISSOLUTION RATE
• The fundamental basis established by Dr. Gordon Amidon
• First introduced into the regulatory decision making process
in the guidance document on Immediate Release Solid Oral
Dosage forms for Scale up and Post Approval changes.
3
What is the need for
classification based on
biopharmaceutics of drug ?
It is important
in determining
Bioavailability
• The principle of the BCS is that if two drug products yield the same
concentration profile along the GIT , they will yield the same plasma
profile after oral administration. This can be summarized by the
following:
where, J is the Flux across the gut wall
Pw is the the permeability of the gut wall to the drug
Cw is the concentration profile at the gut wall
4
J = Pw Cw
OBJECTIVES OF BCS:-
• To identify the challenges of formulation Design.
• To guide decisions w.r.t. IVIVC.
• To improve the efficiency of drug development and identifying
expendable clinical bioequivalence tests.
• To explain when a waiver for in vivo bioavailability and
bioequivalence may be requested.
• To assist in QC in SUPAC.
• To recommend a class of immediate-release (IR) solid oral dosage
forms for which bioequivalence may be assessed based on in vitro
dissolution tests.
• To recommend methods for classification according to dosage form
dissolution along with the solubility-permeability characteristics of
the drug product.
5
FACTORS AFFECTING BCS :-
• The Biopharmaceutical Classification System has been
developed to provide a scientific approach to follow for
prediction of in vivo pharmacokinetics of oral immediate
release (IR) drug product by classifying drug based on:-
6
1. SOLUBILITY
3. DISSOLUTION
RATE
2. PERMEABILITY
1. SOLUBILITY
• The maximum amount of solute dissolved in a given solvent under
standard conditions of temperature, pressure and pH.
• Solubility is the ability of the drug to be solution after dissolution
• A drug substance is classified as ‘HIGHLY SOLUBLE’ if the highest
single therapeutic dose is completely soluble in 250 ml or less of
aqueous media over the pH range of 1.0 – 7.5 at 37 ± 1°C
• Methods for determination of solubility
1. Miniaturized shake-flask method
2. Semi-automated Potentiometric acid/base titrations
3. A computational screening model
4. Miniature device
7
2. PERMEABILITY
• Permeability of the drug to pass the biological membrane.
• Permeability is indirectly based on the extent of absorption of a drug substance .
• Drug substance is considered to be ‘HIGHLY PERMEABLE’, when the extent
of absorption in human determined to be 90% or more of administered drug or
compare to in vivo reference dose.
• Determination of permeability
A. HUMAN PHARMACOKINETIC STUDIES
• Mass balance studies
• Absolute bioavailability studies
B. INTESTINAL PERFUSION METHODS
 In vivo or in situ intestinal perfusion in a suitable animal model.
 In vitro permeability methods using excised intestinal tissues
 In vitro permeation studies across a monolayer of cultured epithelial cells . e.g.
Caco-2 cells or TC-7 cells
8
3. DISSOLUTION
• It is process in which solid substance solubilises in given solvent i.e.
mass transfer from solid surface to liquid phase.
• Using USP apparatus I at 100 rpm or USP apparatus II at 50 rpm .
• Dissolution Media [900 ml],
1. 0.1 N HCl or simulated gastric fluid (pH 1.2)
without enzyme.
2. pH 4.5 buffer & pH 6.8 buffer.
3. Simulated intestinal fluid without enzyme
 Compare dissolution profiles of test and reference products using a
similarity factor (f2).
9
10
Sr.
No.
Dimensionless
Parameter
Ratio of Ideally
should be
Indicative
of
1. Absorption
Number
(An)
Mean Residence
time in G.I.T./
Mean
absorption time
An > 1 G.I.
Permeability
to drug
substance
2. Dissolution
Number
(Dn)
Mean Residence
Time / Mean
Dissolution
Time
Dn > 1 Drug Release
from the
formulation
3. Dose Number
(Do)
(Highest dose/
Volume) /
Solubility
Do < 1 Solubility of
the drug
substance
This classification is associated with drug dissolution and
absorption model, which identifies the key parameters controlling
drug absorption as a set of dimensionless numbers.
CLASSES OF BCS
11
CLASS I
High Solubility
High Permeability
35 % ( in market)
25 % ( NCE)
CLASS III
High Solubility
Low Permeability
25 % (in market)
5 % ( NCE)
CLASS II
Low Solubility
High Permeability
30% (in market)
70% (NCE)
CLASS IV
Low Solubility
Low Permeability
10% (in market)
20% ( NCE)
CLASS I DRUGS
• The drugs of this class exhibit high absorption number
and high dissolution number.
• For those class 1 drugs formulated as IR products,
dissolution rate generally exceeds gastric emptying.
• Behave like an oral solution in-vivo.
• The rate-limiting step is gastric emptying.
• These compounds are well absorbed.
• Absorption rate is usually higher than the excretion rate.
• E.g. Amiloride, Metaprolol, paracetamol etc
12
CLASS II DRUGS
• The drugs of this class have a high absorption number but a
low dissolution number.
• In vivo drug dissolution is then a rate-limiting step for
absorption except at a very high dose number.
• The absorption for Class II drugs is usually slower than for
Class I and occurs over a longer period of time.
• The bioavailability of these products is limited by their
solvation rates.
• Hence, a correlation between the in vivo bioavailability and
the in vitro solvation can be found.
• E.g. Ritonavir, Tamoxifen, Glibenclamide, etc
13
SUBCLASSES OF CLASS II
• Basis- significant impact of pKa on the solubility and
dissolution of drugs.
• BCS Class II drug product dissolution in vitro as well as in
vivo is highly dependent on acidic or basic nature of drug.
• Hence, the class II drugs are sub classified as:
14
CLASS II a
Weakly acidic
drugs
pKa ≤ 5
CLASS II b
Weakly basic
drugs
pKa ≥ 6
CLASS II c
Neutral Drugs
SUB CLASSES OF CLASS II
• Class II a Drugs
• Drugs are insoluble at gastric pH & soluble at intestinal pH
• At intestinal pH (~6.5), the dissolution would increase upto 100 times
• Hence, dissolution rate would be faster than gastric emptying rate
• Thus, these drugs reflect gastric emptying and luminal pH differences.
• Examples- ibuprofen and ketoprofen
CLASS II b DRUGS
• Exhibit high solubility and dissolution rates at acidic pH in stomach
• May precipitate in intestinal pH
• Examples- carvedilol and ketoconazole
CLASS II c DRUGS
• Solubility is not affected by in vivo pH change
• Example- fenofibrate and danazole
15
CLASS III DRUGS
• Drug permeability is the rate-limiting step for drug absorption, but
the drug is solvated very quickly.
• These drugs exhibit a high variation in the rate and extent of drug
absorption.
• Since the dissolution is rapid, the variation is attributable to
alteration of physiology and membrane permeability rather than
dosage form factors.
• E.g. Lisinopril, Atenolol, Cimetidine, etc
• CLASS IV DRUGS
• The drugs of this class are problematic for effective oral
administration.
• These compounds have poor bioavailability.
• They are usually not well absorbed through the intestinal
mucosa, and a high variability is expected.
• E.g. Taxol, Griseofulvin, etc
16
APPLICATIONS
• Application in early drug development and then in
the management of product change through its life
cycle
• Aids fundamental understanding of the
biopharmaceutical and physical properties of the drug
• Aids discriminatory dissolution method development
• Can help guide the development of in-vitro/in-vivo
correlations
• Can be used to obtain a biowaiver
• Development of poorly soluble drugs
17
Applications of BCS in Oral Drug Delivery
system
CLASS I DRUGS.
• Achieve a target release profile associated with a particular pharmacokinetic and/or
pharmacodynamic profile.
• Formulation approaches include both control of release rate and certain
physicochemical properties of drugs like pH-solubility profile of drug
• Pregabalin is a BCS Class 1 compound (highly permeable and highly soluble).
Pregabalin is an amino acid and its lowest aqueous solubility occurs at its
isoelectric point (at pH 7.4). It is considered high solubility as the amount of
water needed (<10 mL) to dissolve the highest dose strength (300 mg) at pH 7.4
is less than the 250 mL criteria. Pregabalin meets the BCS criteria for a highly
permeable compound as greater than 90% of the dose is excreted unchanged
in the urine
CLASS II DRUGS
• Micronisation
18
• Addition of surfactants
• Solid dispersions
• Salt Formation
• Formulation as emulsions and microemulsions systems
• Use of complexing agents like cyclodextrins
• Solid dispersions of ezetimibe were prepared by melt extrusion
method using Kollidon VA64 as carrier. Solid dispersions have
exhibited very high solubility in pH 4.5 acetate buffer than the other
buffer media. The ezetimibe drug content in all the dispersions were
found to be in the range of 99.6 to 99.76 %.
CLASS III DRUGS
• Require the technologies that address to fundamental limitations of
absolute or regional permeability.
• Peptides and proteins constitute the part of class III and the technologies
handling such materials are on rise now days
19
The different formulation strategies for enhancement of oral bioavailability of
BCS class III drugs over here is categorized into (a) formulations imparting
lipophilic character to drug and (b) formulations that increase gastric retention
time of drug.
Double emulsion
Niosomes
CLASS IV DRUGS
• Major challenge for development of drug delivery system and the route of
choice for administering such drugs is parenteral (solubility enhancers.)
• Hydrochlorothiazide (HCTZ)7 which is a well categorized
• Thiazide diuretic, considered as the first-line of treatment for hypertension and
listed as an essential medicine in WHO list. Although, it’s an essential
medication but due to its low bioavailability (65%) low permeability9 and
extensive hepatic metabolism, it loses its therapeutic efficacy. Hence, to evade
all these limitations an up graded delivery mechanisms are required which can
be attained by designing the polymer based nanoparticle drug delivery system.
20
21
BIOWAVER
• A BIOWAIVER is an exemption from conducting human bioequivalence
studies when the active ingredient(s) meet certain solubility and
permeability criteria in vitro and when the dissolution profile of the dosage
form meets the requirements for an "immediate" release dosage form.
• PREREQUISITES FOR BIO WAVER ( ICH M9 guideline)
• Rapid and similar dissolution.
• High solubility & High permeability.
• Wide therapeutic window.
• Excipients used in dosage form used previously in approved IR
solid dosage forms.
22
REQUEST FOR BIOWAVER
Data Supporting Rapid and
Similar Dissolution
Data supporting High
Permeability
Data supporting High
Solubility
Dissolution data obtained with
12 individual units of the test
and reference products at each
specified testing interval for
each individual dosage unit. A
graphic representation of the
mean dissolution profiles for
the test and reference products
in the three media.
· Data supporting similarity
in dissolution profiles between
the test and reference products
in each of the three media,
using the f2 metric.
For direct permeability
methods, information
supporting method suitability
with a description of the study
method, criteria for selection of
human subjects, animals, or
epithelial cell line, drug
concentrations, description of
the analytical method, method
to calculate extent of
absorption or permeability, and
information on efflux potential
(if appropriate).
Description of test methods
(analytical method, buffer
composition).
· Information on chemical
structure, molecular weight,
nature of drug substance,
dissociation constants.
· Test results summarized
in a table with solution pH,
drug solubility, volume to
dissolve highest dose strength.
· Graphical representation
of mean pH-solubility profile
23
24
ACCEPTANCE REJECTION
• Immediate release, solid orally
administered dosage forms or suspensions
designed to deliver drug to the systemic
circulation
• Where the drug substances exhibit high
solubility and, either high permeability
(BCS Class I) or low permeability (BCS
Class III)
• When the drug substances in test and
reference products are identical even if
they contain different salts provided that
both belong to BCS Class I (high
solubility and high permeability).
• Drug products having a narrow
therapeutic index
• When the test product contains a
different ester, ether, isomer, mixture of
isomers, complex or derivative of a drug
substance from that of the reference
product, since these differences may lead
to different bio availabilities .
•Drug products with buccal or sublingual
absorption
ELIGIBILITY CRITERIA FOR BIOWAVER
EXCIPIENTS INCLUDED
• Ideally, the composition of the test product should mimic
that of the reference product.
• However, where excipient differences exist, they should
be assessed for their potential to affect in vivo absorption.
• This should include consideration of the drug substance
properties as well as excipient effects.
• To be eligible for a BCS-based biowaiver, the sponsor
should justify why the proposed excipient differences will
not affect the absorption profile of the drug substance
under consideration, i.e., rate and extent of absorption,
using a mechanistic and risk-based approach.
25
LIMITATIONS OF BCS
• Effects of Food, Absorptive transporters, Efflux transporters &
Routes of elimination(renal/biliary) are important determinants of
BA for immediate release oral dosage forms, which are not
considered in BCS.
• Limitations of BCS as a Predictor of Drug Disposition
• Permeability (90% absorption) is difficult to determine, and
difficult to convince the regulatory agency .
• There is little predictability for BCS classification drugs beyond
Class 1 primarily due to the difficulty of
• determining and proving 90% absorption, many drugs are
misclassified (e.g. HIV protease inhibitors as Class 4 compounds).
26
EXTENSIONS TO BCS
1. Six class BCS:
• The drugs are classified into six classes.
• The solubility was classified as “low” or “high”
permeability was allotted as “low” “intermediate” or
“high”.
2. Quantitative BCS (QBCS):
• Quantitative BCS (QBCS) was developed using the dose:
solubility ratio as core parameter for classification.
• States that solubility is a static equilibrium parameter and
cannot describe the dynamic character of the dissolution
process for the entire dose administered.
27
3. Pulmonary BCS
• The BCS is limited to the gastrointestinal tract.
• The pulmonary BCS (PBCS) consider the specific biology of
the lung as well as particle deposition, aerosol physics, and
the subsequent processes of drug absorption and solubility
4. BDDCS CLASSIFICATION
• BDDCS (Biopharmaceutical Drug Disposition and
Classification System) divides compounds into four classes
based on their permeability and solubility.
• This classification system is useful in predicting effects of
efflux and uptake transporters on oral absorption as well as
on post absorption systemic levels following oral and
intravenous dosing.
28
BDDCS
29
CONCLUSION
• BCS aims to provide a regulatory tool for replacing certain
BE studies by accurate in vitro dissolution tests.
• This increased awareness of a proper biopharmaceutical
characterization of new drugs may in the future result in drug
molecules with a sufficiently high permeability, solubility
and dissolution rate and that will automatically increase the
importance of the BCS as a regulatory tool over time
30
REFERENCES
• Brahmankar, D. M and Jaiswal, Sunil. B (2009). Biopharmaceutics and Pharmacokinetics – A
Treatise. 2nd edition. Vallabh Prakashan, Page no. 27-29 and 332 - 335.
• Leon shargel, Susanna wu-pong, Andrew B.C.Yu , Applied Biopharmaceutics &
Pharmacokinetics, 5th edition 2005, published by the Mc Graw hills companies, page no.
431-436 & 482-484.
• Wagh M.P, Patel J.S., 2010, International Journal of Pharmacy and Pharmaceutical Sciences,
Vol 2, Page 12-19
• SV Deshmane, PP Chinchole, RM Gaurkhede, MA Channawar, AV Chandewar. The
Biopharmaceutics Classification System: A Review. Research J. Pharm. and Tech. 2(1): Jan.-
Mar. 2009; Page 8-11
• General Notes on Biopharmaceutics Classification System (BCS)- based Biowaiver
Applications by WHO
• ICH M9 Guideline.
• Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation
development. J Control Release. 2017 Feb 28;248:71-95
• Ashis kumar mehatha, vidyadhara Suryadevara*, sasidhar R lankapalli , abhijit M deshmukh,
laxmana p sambath , 2014, turk j pharm sci, formulation and optimization of ezetimibe
containing solid dispersions using kollidon VA64, 113-126
• Pregabalin zentiva assessment report (EMEA)
31

Contenu connexe

Tendances

bioequivalence study design
bioequivalence study designbioequivalence study design
bioequivalence study designJuhi Priya
 
Preformulation stability study
Preformulation stability studyPreformulation stability study
Preformulation stability studyArabinda Changmai
 
Biopharmaceutical Classification System (BCS)
Biopharmaceutical Classification System (BCS)Biopharmaceutical Classification System (BCS)
Biopharmaceutical Classification System (BCS)Suraj Khali
 
Bcs classification by sneha gaurkar
Bcs classification by sneha gaurkarBcs classification by sneha gaurkar
Bcs classification by sneha gaurkarSneha Gaurkar
 
Drug excepients compatability studies
Drug excepients compatability studiesDrug excepients compatability studies
Drug excepients compatability studieskinju19
 
Dissolution profile comparison
Dissolution profile comparisonDissolution profile comparison
Dissolution profile comparisonMohammad Imran
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
 
regulatory requirement for bioequivalence
regulatory requirement for bioequivalenceregulatory requirement for bioequivalence
regulatory requirement for bioequivalencelamrin33
 
Dissolution testing conventional and controlled release products
Dissolution testing  conventional and controlled release productsDissolution testing  conventional and controlled release products
Dissolution testing conventional and controlled release productsMd Fiaz
 
Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...
Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...
Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...Manikant Prasad Shah
 
Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Sagar Savale
 
factors affecting dissolution rate a full view.
 factors affecting dissolution rate a full view. factors affecting dissolution rate a full view.
factors affecting dissolution rate a full view.aishwaryashiremath
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient CompatibilitySuraj Choudhary
 
Biopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailabilityBiopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailabilitySyed Rashed Faizan Mehdi
 
Physicochemical and biological properties of sustained release formulations
Physicochemical and biological properties of sustained release formulationsPhysicochemical and biological properties of sustained release formulations
Physicochemical and biological properties of sustained release formulationsSonam Gandhi
 
Sustained release dosage form [srdf]
Sustained release dosage form [srdf]Sustained release dosage form [srdf]
Sustained release dosage form [srdf]Sagar Savale
 

Tendances (20)

bioequivalence study design
bioequivalence study designbioequivalence study design
bioequivalence study design
 
Preformulation stability study
Preformulation stability studyPreformulation stability study
Preformulation stability study
 
Biopharmaceutical Classification System (BCS)
Biopharmaceutical Classification System (BCS)Biopharmaceutical Classification System (BCS)
Biopharmaceutical Classification System (BCS)
 
Biowaivers
BiowaiversBiowaivers
Biowaivers
 
Bcs classification by sneha gaurkar
Bcs classification by sneha gaurkarBcs classification by sneha gaurkar
Bcs classification by sneha gaurkar
 
Drug excepients compatability studies
Drug excepients compatability studiesDrug excepients compatability studies
Drug excepients compatability studies
 
Dissolution profile comparison
Dissolution profile comparisonDissolution profile comparison
Dissolution profile comparison
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
 
regulatory requirement for bioequivalence
regulatory requirement for bioequivalenceregulatory requirement for bioequivalence
regulatory requirement for bioequivalence
 
Dissolution testing conventional and controlled release products
Dissolution testing  conventional and controlled release productsDissolution testing  conventional and controlled release products
Dissolution testing conventional and controlled release products
 
Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...
Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...
Bioavailability , absolute bioavalability, relative bioavailability, Purpose ...
 
Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]
 
factors affecting dissolution rate a full view.
 factors affecting dissolution rate a full view. factors affecting dissolution rate a full view.
factors affecting dissolution rate a full view.
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient Compatibility
 
Bioequivalence Studies
Bioequivalence StudiesBioequivalence Studies
Bioequivalence Studies
 
Dissolution methods
Dissolution methodsDissolution methods
Dissolution methods
 
Biopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailabilityBiopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailability
 
Dissolution
DissolutionDissolution
Dissolution
 
Physicochemical and biological properties of sustained release formulations
Physicochemical and biological properties of sustained release formulationsPhysicochemical and biological properties of sustained release formulations
Physicochemical and biological properties of sustained release formulations
 
Sustained release dosage form [srdf]
Sustained release dosage form [srdf]Sustained release dosage form [srdf]
Sustained release dosage form [srdf]
 

Similaire à Biopharmaceutical Classification System

BCS Guideline for solubility and Dissolution.pptx
BCS Guideline for solubility and Dissolution.pptxBCS Guideline for solubility and Dissolution.pptx
BCS Guideline for solubility and Dissolution.pptxImdad H. Mukeri
 
Bcs classification of drug
Bcs classification of drugBcs classification of drug
Bcs classification of drugManojKumar109262
 
Biopharmaceutical classification system
Biopharmaceutical classification systemBiopharmaceutical classification system
Biopharmaceutical classification systemArpitha Aarushi
 
BCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptxBCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptxNishaN19p7504
 
BCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdfBCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdfAsif Shaikh
 
Biopharmaceutical classification system & drug delivery system associated wit...
Biopharmaceutical classification system & drug delivery system associated wit...Biopharmaceutical classification system & drug delivery system associated wit...
Biopharmaceutical classification system & drug delivery system associated wit...PratikShinde120
 
Biopharmaceutics Presentation Topic- BCS Classification
Biopharmaceutics Presentation Topic- BCS ClassificationBiopharmaceutics Presentation Topic- BCS Classification
Biopharmaceutics Presentation Topic- BCS ClassificationRishabh Sharma
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification systemReshma Fathima .K
 
Biopharmaceutical classification system.
Biopharmaceutical classification system.Biopharmaceutical classification system.
Biopharmaceutical classification system.Smritibhanu
 
COMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEM
COMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEMCOMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEM
COMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEMArunpandiyan59
 
biopharmaceutics classification system.pptx
biopharmaceutics classification system.pptxbiopharmaceutics classification system.pptx
biopharmaceutics classification system.pptxanumalagundam sreekanth
 
Dissolution_Technique.ppt
Dissolution_Technique.pptDissolution_Technique.ppt
Dissolution_Technique.pptRavi Kumar G
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification systemAzka Shakeeb
 
Controlled Release Drug Delivery Systems - Types, Methods and Applications
Controlled Release Drug Delivery Systems - Types, Methods and ApplicationsControlled Release Drug Delivery Systems - Types, Methods and Applications
Controlled Release Drug Delivery Systems - Types, Methods and ApplicationsSuraj Choudhary
 
2.Sagar Goda Biological classification system (BCS); its significance on diss...
2.Sagar Goda Biological classification system (BCS); its significance on diss...2.Sagar Goda Biological classification system (BCS); its significance on diss...
2.Sagar Goda Biological classification system (BCS); its significance on diss...Sagar Goda
 
NOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptx
NOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptxNOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptx
NOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptxJUGANTA KUMAR KALITA
 
Controlled release drug delivery system
Controlled release drug delivery system Controlled release drug delivery system
Controlled release drug delivery system MOHAMMEDABDULSALAM32
 

Similaire à Biopharmaceutical Classification System (20)

BCS Guideline for solubility and Dissolution.pptx
BCS Guideline for solubility and Dissolution.pptxBCS Guideline for solubility and Dissolution.pptx
BCS Guideline for solubility and Dissolution.pptx
 
Bcs classification of drug
Bcs classification of drugBcs classification of drug
Bcs classification of drug
 
Biopharmaceutical classification system
Biopharmaceutical classification systemBiopharmaceutical classification system
Biopharmaceutical classification system
 
BCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptxBCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptx
 
BCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdfBCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdf
 
Biopharmaceutical classification system & drug delivery system associated wit...
Biopharmaceutical classification system & drug delivery system associated wit...Biopharmaceutical classification system & drug delivery system associated wit...
Biopharmaceutical classification system & drug delivery system associated wit...
 
Bcs classification system
Bcs classification system Bcs classification system
Bcs classification system
 
Biopharmaceutics Presentation Topic- BCS Classification
Biopharmaceutics Presentation Topic- BCS ClassificationBiopharmaceutics Presentation Topic- BCS Classification
Biopharmaceutics Presentation Topic- BCS Classification
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification system
 
Biopharmaceutical classification system.
Biopharmaceutical classification system.Biopharmaceutical classification system.
Biopharmaceutical classification system.
 
COMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEM
COMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEMCOMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEM
COMPOUNDS THAT CANNOT BE FORMULATED AS CONTROLLED RELEASE SYSTEM
 
Jatin ivivc
Jatin ivivcJatin ivivc
Jatin ivivc
 
biopharmaceutics classification system.pptx
biopharmaceutics classification system.pptxbiopharmaceutics classification system.pptx
biopharmaceutics classification system.pptx
 
Dissolution_Technique.ppt
Dissolution_Technique.pptDissolution_Technique.ppt
Dissolution_Technique.ppt
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification system
 
Controlled Release Drug Delivery Systems - Types, Methods and Applications
Controlled Release Drug Delivery Systems - Types, Methods and ApplicationsControlled Release Drug Delivery Systems - Types, Methods and Applications
Controlled Release Drug Delivery Systems - Types, Methods and Applications
 
2.Sagar Goda Biological classification system (BCS); its significance on diss...
2.Sagar Goda Biological classification system (BCS); its significance on diss...2.Sagar Goda Biological classification system (BCS); its significance on diss...
2.Sagar Goda Biological classification system (BCS); its significance on diss...
 
NOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptx
NOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptxNOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptx
NOVEL DRUG DELIVERY SYSTEM by Juganta kr kalita.pptx
 
Invitro dissolution
Invitro dissolutionInvitro dissolution
Invitro dissolution
 
Controlled release drug delivery system
Controlled release drug delivery system Controlled release drug delivery system
Controlled release drug delivery system
 

Dernier

Awards Presentation 2024 - March 12 2024
Awards Presentation 2024 - March 12 2024Awards Presentation 2024 - March 12 2024
Awards Presentation 2024 - March 12 2024bsellato
 
25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...
25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...
25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...Nguyen Thanh Tu Collection
 
Riti theory by Vamana Indian poetics.pptx
Riti theory by Vamana Indian poetics.pptxRiti theory by Vamana Indian poetics.pptx
Riti theory by Vamana Indian poetics.pptxDhatriParmar
 
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYSDLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYSTeacherNicaPrintable
 
Research Methodology and Tips on Better Research
Research Methodology and Tips on Better ResearchResearch Methodology and Tips on Better Research
Research Methodology and Tips on Better ResearchRushdi Shams
 
3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptx3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptxmary850239
 
Auchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian PoeticsAuchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian PoeticsDhatriParmar
 
2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...Sandy Millin
 
BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...
BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...
BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...Nguyen Thanh Tu Collection
 
VIT336 – Recommender System - Unit 3.pdf
VIT336 – Recommender System - Unit 3.pdfVIT336 – Recommender System - Unit 3.pdf
VIT336 – Recommender System - Unit 3.pdfArthyR3
 
EDD8524 The Future of Educational Leader
EDD8524 The Future of Educational LeaderEDD8524 The Future of Educational Leader
EDD8524 The Future of Educational LeaderDr. Bruce A. Johnson
 
3.14.24 The Selma March and the Voting Rights Act.pptx
3.14.24 The Selma March and the Voting Rights Act.pptx3.14.24 The Selma March and the Voting Rights Act.pptx
3.14.24 The Selma March and the Voting Rights Act.pptxmary850239
 
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdfPHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdfSumit Tiwari
 
Metabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptxMetabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptxDr. Santhosh Kumar. N
 
3.12.24 Freedom Summer in Mississippi.pptx
3.12.24 Freedom Summer in Mississippi.pptx3.12.24 Freedom Summer in Mississippi.pptx
3.12.24 Freedom Summer in Mississippi.pptxmary850239
 
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...AKSHAYMAGAR17
 
The First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdfThe First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdfdogden2
 
THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...
THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...
THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...Subham Panja
 
BBA 205 BUSINESS ENVIRONMENT UNIT I.pptx
BBA 205 BUSINESS ENVIRONMENT UNIT I.pptxBBA 205 BUSINESS ENVIRONMENT UNIT I.pptx
BBA 205 BUSINESS ENVIRONMENT UNIT I.pptxProf. Kanchan Kumari
 

Dernier (20)

Awards Presentation 2024 - March 12 2024
Awards Presentation 2024 - March 12 2024Awards Presentation 2024 - March 12 2024
Awards Presentation 2024 - March 12 2024
 
25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...
25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...
25 CHUYÊN ĐỀ ÔN THI TỐT NGHIỆP THPT 2023 – BÀI TẬP PHÁT TRIỂN TỪ ĐỀ MINH HỌA...
 
Riti theory by Vamana Indian poetics.pptx
Riti theory by Vamana Indian poetics.pptxRiti theory by Vamana Indian poetics.pptx
Riti theory by Vamana Indian poetics.pptx
 
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYSDLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
 
Research Methodology and Tips on Better Research
Research Methodology and Tips on Better ResearchResearch Methodology and Tips on Better Research
Research Methodology and Tips on Better Research
 
3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptx3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptx
 
Auchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian PoeticsAuchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian Poetics
 
2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...
 
BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...
BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...
BÀI TẬP BỔ TRỢ TIẾNG ANH 11 THEO ĐƠN VỊ BÀI HỌC - CẢ NĂM - CÓ FILE NGHE (GLOB...
 
VIT336 – Recommender System - Unit 3.pdf
VIT336 – Recommender System - Unit 3.pdfVIT336 – Recommender System - Unit 3.pdf
VIT336 – Recommender System - Unit 3.pdf
 
EDD8524 The Future of Educational Leader
EDD8524 The Future of Educational LeaderEDD8524 The Future of Educational Leader
EDD8524 The Future of Educational Leader
 
3.14.24 The Selma March and the Voting Rights Act.pptx
3.14.24 The Selma March and the Voting Rights Act.pptx3.14.24 The Selma March and the Voting Rights Act.pptx
3.14.24 The Selma March and the Voting Rights Act.pptx
 
Least Significance Difference:Biostatics and Research Methodology
Least Significance Difference:Biostatics and Research MethodologyLeast Significance Difference:Biostatics and Research Methodology
Least Significance Difference:Biostatics and Research Methodology
 
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdfPHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
 
Metabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptxMetabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptx
 
3.12.24 Freedom Summer in Mississippi.pptx
3.12.24 Freedom Summer in Mississippi.pptx3.12.24 Freedom Summer in Mississippi.pptx
3.12.24 Freedom Summer in Mississippi.pptx
 
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
 
The First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdfThe First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdf
 
THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...
THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...
THYROID HORMONE.pptx by Subham Panja,Asst. Professor, Department of B.Sc MLT,...
 
BBA 205 BUSINESS ENVIRONMENT UNIT I.pptx
BBA 205 BUSINESS ENVIRONMENT UNIT I.pptxBBA 205 BUSINESS ENVIRONMENT UNIT I.pptx
BBA 205 BUSINESS ENVIRONMENT UNIT I.pptx
 

Biopharmaceutical Classification System

  • 1. BIOPHARMACEUTICAL CLASSIFICATION SYSTEM (BCS) Presented By:- Vaishnavi A. Bhosale M.S. Pharmaceutics ( 1st Semester) NIPER Hyderabad 1
  • 2. CONTENTS: • Introduction • Objectives of BCS • Factors affecting BCS Classification • Classes of BCS • Applications • Bio wavers • Limitations of BCS • Extensions to BCS • Conclusion 2
  • 3. INTRODUCTION • BCS is a scientific framework for classifying drugs based on their AQUEOUS SOLUBILITY, INTESTINAL PERMEABILITY and DISSOLUTION RATE • The fundamental basis established by Dr. Gordon Amidon • First introduced into the regulatory decision making process in the guidance document on Immediate Release Solid Oral Dosage forms for Scale up and Post Approval changes. 3 What is the need for classification based on biopharmaceutics of drug ? It is important in determining Bioavailability
  • 4. • The principle of the BCS is that if two drug products yield the same concentration profile along the GIT , they will yield the same plasma profile after oral administration. This can be summarized by the following: where, J is the Flux across the gut wall Pw is the the permeability of the gut wall to the drug Cw is the concentration profile at the gut wall 4 J = Pw Cw
  • 5. OBJECTIVES OF BCS:- • To identify the challenges of formulation Design. • To guide decisions w.r.t. IVIVC. • To improve the efficiency of drug development and identifying expendable clinical bioequivalence tests. • To explain when a waiver for in vivo bioavailability and bioequivalence may be requested. • To assist in QC in SUPAC. • To recommend a class of immediate-release (IR) solid oral dosage forms for which bioequivalence may be assessed based on in vitro dissolution tests. • To recommend methods for classification according to dosage form dissolution along with the solubility-permeability characteristics of the drug product. 5
  • 6. FACTORS AFFECTING BCS :- • The Biopharmaceutical Classification System has been developed to provide a scientific approach to follow for prediction of in vivo pharmacokinetics of oral immediate release (IR) drug product by classifying drug based on:- 6 1. SOLUBILITY 3. DISSOLUTION RATE 2. PERMEABILITY
  • 7. 1. SOLUBILITY • The maximum amount of solute dissolved in a given solvent under standard conditions of temperature, pressure and pH. • Solubility is the ability of the drug to be solution after dissolution • A drug substance is classified as ‘HIGHLY SOLUBLE’ if the highest single therapeutic dose is completely soluble in 250 ml or less of aqueous media over the pH range of 1.0 – 7.5 at 37 ± 1°C • Methods for determination of solubility 1. Miniaturized shake-flask method 2. Semi-automated Potentiometric acid/base titrations 3. A computational screening model 4. Miniature device 7
  • 8. 2. PERMEABILITY • Permeability of the drug to pass the biological membrane. • Permeability is indirectly based on the extent of absorption of a drug substance . • Drug substance is considered to be ‘HIGHLY PERMEABLE’, when the extent of absorption in human determined to be 90% or more of administered drug or compare to in vivo reference dose. • Determination of permeability A. HUMAN PHARMACOKINETIC STUDIES • Mass balance studies • Absolute bioavailability studies B. INTESTINAL PERFUSION METHODS  In vivo or in situ intestinal perfusion in a suitable animal model.  In vitro permeability methods using excised intestinal tissues  In vitro permeation studies across a monolayer of cultured epithelial cells . e.g. Caco-2 cells or TC-7 cells 8
  • 9. 3. DISSOLUTION • It is process in which solid substance solubilises in given solvent i.e. mass transfer from solid surface to liquid phase. • Using USP apparatus I at 100 rpm or USP apparatus II at 50 rpm . • Dissolution Media [900 ml], 1. 0.1 N HCl or simulated gastric fluid (pH 1.2) without enzyme. 2. pH 4.5 buffer & pH 6.8 buffer. 3. Simulated intestinal fluid without enzyme  Compare dissolution profiles of test and reference products using a similarity factor (f2). 9
  • 10. 10 Sr. No. Dimensionless Parameter Ratio of Ideally should be Indicative of 1. Absorption Number (An) Mean Residence time in G.I.T./ Mean absorption time An > 1 G.I. Permeability to drug substance 2. Dissolution Number (Dn) Mean Residence Time / Mean Dissolution Time Dn > 1 Drug Release from the formulation 3. Dose Number (Do) (Highest dose/ Volume) / Solubility Do < 1 Solubility of the drug substance This classification is associated with drug dissolution and absorption model, which identifies the key parameters controlling drug absorption as a set of dimensionless numbers.
  • 11. CLASSES OF BCS 11 CLASS I High Solubility High Permeability 35 % ( in market) 25 % ( NCE) CLASS III High Solubility Low Permeability 25 % (in market) 5 % ( NCE) CLASS II Low Solubility High Permeability 30% (in market) 70% (NCE) CLASS IV Low Solubility Low Permeability 10% (in market) 20% ( NCE)
  • 12. CLASS I DRUGS • The drugs of this class exhibit high absorption number and high dissolution number. • For those class 1 drugs formulated as IR products, dissolution rate generally exceeds gastric emptying. • Behave like an oral solution in-vivo. • The rate-limiting step is gastric emptying. • These compounds are well absorbed. • Absorption rate is usually higher than the excretion rate. • E.g. Amiloride, Metaprolol, paracetamol etc 12
  • 13. CLASS II DRUGS • The drugs of this class have a high absorption number but a low dissolution number. • In vivo drug dissolution is then a rate-limiting step for absorption except at a very high dose number. • The absorption for Class II drugs is usually slower than for Class I and occurs over a longer period of time. • The bioavailability of these products is limited by their solvation rates. • Hence, a correlation between the in vivo bioavailability and the in vitro solvation can be found. • E.g. Ritonavir, Tamoxifen, Glibenclamide, etc 13
  • 14. SUBCLASSES OF CLASS II • Basis- significant impact of pKa on the solubility and dissolution of drugs. • BCS Class II drug product dissolution in vitro as well as in vivo is highly dependent on acidic or basic nature of drug. • Hence, the class II drugs are sub classified as: 14 CLASS II a Weakly acidic drugs pKa ≤ 5 CLASS II b Weakly basic drugs pKa ≥ 6 CLASS II c Neutral Drugs
  • 15. SUB CLASSES OF CLASS II • Class II a Drugs • Drugs are insoluble at gastric pH & soluble at intestinal pH • At intestinal pH (~6.5), the dissolution would increase upto 100 times • Hence, dissolution rate would be faster than gastric emptying rate • Thus, these drugs reflect gastric emptying and luminal pH differences. • Examples- ibuprofen and ketoprofen CLASS II b DRUGS • Exhibit high solubility and dissolution rates at acidic pH in stomach • May precipitate in intestinal pH • Examples- carvedilol and ketoconazole CLASS II c DRUGS • Solubility is not affected by in vivo pH change • Example- fenofibrate and danazole 15
  • 16. CLASS III DRUGS • Drug permeability is the rate-limiting step for drug absorption, but the drug is solvated very quickly. • These drugs exhibit a high variation in the rate and extent of drug absorption. • Since the dissolution is rapid, the variation is attributable to alteration of physiology and membrane permeability rather than dosage form factors. • E.g. Lisinopril, Atenolol, Cimetidine, etc • CLASS IV DRUGS • The drugs of this class are problematic for effective oral administration. • These compounds have poor bioavailability. • They are usually not well absorbed through the intestinal mucosa, and a high variability is expected. • E.g. Taxol, Griseofulvin, etc 16
  • 17. APPLICATIONS • Application in early drug development and then in the management of product change through its life cycle • Aids fundamental understanding of the biopharmaceutical and physical properties of the drug • Aids discriminatory dissolution method development • Can help guide the development of in-vitro/in-vivo correlations • Can be used to obtain a biowaiver • Development of poorly soluble drugs 17
  • 18. Applications of BCS in Oral Drug Delivery system CLASS I DRUGS. • Achieve a target release profile associated with a particular pharmacokinetic and/or pharmacodynamic profile. • Formulation approaches include both control of release rate and certain physicochemical properties of drugs like pH-solubility profile of drug • Pregabalin is a BCS Class 1 compound (highly permeable and highly soluble). Pregabalin is an amino acid and its lowest aqueous solubility occurs at its isoelectric point (at pH 7.4). It is considered high solubility as the amount of water needed (<10 mL) to dissolve the highest dose strength (300 mg) at pH 7.4 is less than the 250 mL criteria. Pregabalin meets the BCS criteria for a highly permeable compound as greater than 90% of the dose is excreted unchanged in the urine CLASS II DRUGS • Micronisation 18
  • 19. • Addition of surfactants • Solid dispersions • Salt Formation • Formulation as emulsions and microemulsions systems • Use of complexing agents like cyclodextrins • Solid dispersions of ezetimibe were prepared by melt extrusion method using Kollidon VA64 as carrier. Solid dispersions have exhibited very high solubility in pH 4.5 acetate buffer than the other buffer media. The ezetimibe drug content in all the dispersions were found to be in the range of 99.6 to 99.76 %. CLASS III DRUGS • Require the technologies that address to fundamental limitations of absolute or regional permeability. • Peptides and proteins constitute the part of class III and the technologies handling such materials are on rise now days 19
  • 20. The different formulation strategies for enhancement of oral bioavailability of BCS class III drugs over here is categorized into (a) formulations imparting lipophilic character to drug and (b) formulations that increase gastric retention time of drug. Double emulsion Niosomes CLASS IV DRUGS • Major challenge for development of drug delivery system and the route of choice for administering such drugs is parenteral (solubility enhancers.) • Hydrochlorothiazide (HCTZ)7 which is a well categorized • Thiazide diuretic, considered as the first-line of treatment for hypertension and listed as an essential medicine in WHO list. Although, it’s an essential medication but due to its low bioavailability (65%) low permeability9 and extensive hepatic metabolism, it loses its therapeutic efficacy. Hence, to evade all these limitations an up graded delivery mechanisms are required which can be attained by designing the polymer based nanoparticle drug delivery system. 20
  • 21. 21
  • 22. BIOWAVER • A BIOWAIVER is an exemption from conducting human bioequivalence studies when the active ingredient(s) meet certain solubility and permeability criteria in vitro and when the dissolution profile of the dosage form meets the requirements for an "immediate" release dosage form. • PREREQUISITES FOR BIO WAVER ( ICH M9 guideline) • Rapid and similar dissolution. • High solubility & High permeability. • Wide therapeutic window. • Excipients used in dosage form used previously in approved IR solid dosage forms. 22
  • 23. REQUEST FOR BIOWAVER Data Supporting Rapid and Similar Dissolution Data supporting High Permeability Data supporting High Solubility Dissolution data obtained with 12 individual units of the test and reference products at each specified testing interval for each individual dosage unit. A graphic representation of the mean dissolution profiles for the test and reference products in the three media. · Data supporting similarity in dissolution profiles between the test and reference products in each of the three media, using the f2 metric. For direct permeability methods, information supporting method suitability with a description of the study method, criteria for selection of human subjects, animals, or epithelial cell line, drug concentrations, description of the analytical method, method to calculate extent of absorption or permeability, and information on efflux potential (if appropriate). Description of test methods (analytical method, buffer composition). · Information on chemical structure, molecular weight, nature of drug substance, dissociation constants. · Test results summarized in a table with solution pH, drug solubility, volume to dissolve highest dose strength. · Graphical representation of mean pH-solubility profile 23
  • 24. 24 ACCEPTANCE REJECTION • Immediate release, solid orally administered dosage forms or suspensions designed to deliver drug to the systemic circulation • Where the drug substances exhibit high solubility and, either high permeability (BCS Class I) or low permeability (BCS Class III) • When the drug substances in test and reference products are identical even if they contain different salts provided that both belong to BCS Class I (high solubility and high permeability). • Drug products having a narrow therapeutic index • When the test product contains a different ester, ether, isomer, mixture of isomers, complex or derivative of a drug substance from that of the reference product, since these differences may lead to different bio availabilities . •Drug products with buccal or sublingual absorption ELIGIBILITY CRITERIA FOR BIOWAVER
  • 25. EXCIPIENTS INCLUDED • Ideally, the composition of the test product should mimic that of the reference product. • However, where excipient differences exist, they should be assessed for their potential to affect in vivo absorption. • This should include consideration of the drug substance properties as well as excipient effects. • To be eligible for a BCS-based biowaiver, the sponsor should justify why the proposed excipient differences will not affect the absorption profile of the drug substance under consideration, i.e., rate and extent of absorption, using a mechanistic and risk-based approach. 25
  • 26. LIMITATIONS OF BCS • Effects of Food, Absorptive transporters, Efflux transporters & Routes of elimination(renal/biliary) are important determinants of BA for immediate release oral dosage forms, which are not considered in BCS. • Limitations of BCS as a Predictor of Drug Disposition • Permeability (90% absorption) is difficult to determine, and difficult to convince the regulatory agency . • There is little predictability for BCS classification drugs beyond Class 1 primarily due to the difficulty of • determining and proving 90% absorption, many drugs are misclassified (e.g. HIV protease inhibitors as Class 4 compounds). 26
  • 27. EXTENSIONS TO BCS 1. Six class BCS: • The drugs are classified into six classes. • The solubility was classified as “low” or “high” permeability was allotted as “low” “intermediate” or “high”. 2. Quantitative BCS (QBCS): • Quantitative BCS (QBCS) was developed using the dose: solubility ratio as core parameter for classification. • States that solubility is a static equilibrium parameter and cannot describe the dynamic character of the dissolution process for the entire dose administered. 27
  • 28. 3. Pulmonary BCS • The BCS is limited to the gastrointestinal tract. • The pulmonary BCS (PBCS) consider the specific biology of the lung as well as particle deposition, aerosol physics, and the subsequent processes of drug absorption and solubility 4. BDDCS CLASSIFICATION • BDDCS (Biopharmaceutical Drug Disposition and Classification System) divides compounds into four classes based on their permeability and solubility. • This classification system is useful in predicting effects of efflux and uptake transporters on oral absorption as well as on post absorption systemic levels following oral and intravenous dosing. 28
  • 30. CONCLUSION • BCS aims to provide a regulatory tool for replacing certain BE studies by accurate in vitro dissolution tests. • This increased awareness of a proper biopharmaceutical characterization of new drugs may in the future result in drug molecules with a sufficiently high permeability, solubility and dissolution rate and that will automatically increase the importance of the BCS as a regulatory tool over time 30
  • 31. REFERENCES • Brahmankar, D. M and Jaiswal, Sunil. B (2009). Biopharmaceutics and Pharmacokinetics – A Treatise. 2nd edition. Vallabh Prakashan, Page no. 27-29 and 332 - 335. • Leon shargel, Susanna wu-pong, Andrew B.C.Yu , Applied Biopharmaceutics & Pharmacokinetics, 5th edition 2005, published by the Mc Graw hills companies, page no. 431-436 & 482-484. • Wagh M.P, Patel J.S., 2010, International Journal of Pharmacy and Pharmaceutical Sciences, Vol 2, Page 12-19 • SV Deshmane, PP Chinchole, RM Gaurkhede, MA Channawar, AV Chandewar. The Biopharmaceutics Classification System: A Review. Research J. Pharm. and Tech. 2(1): Jan.- Mar. 2009; Page 8-11 • General Notes on Biopharmaceutics Classification System (BCS)- based Biowaiver Applications by WHO • ICH M9 Guideline. • Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release. 2017 Feb 28;248:71-95 • Ashis kumar mehatha, vidyadhara Suryadevara*, sasidhar R lankapalli , abhijit M deshmukh, laxmana p sambath , 2014, turk j pharm sci, formulation and optimization of ezetimibe containing solid dispersions using kollidon VA64, 113-126 • Pregabalin zentiva assessment report (EMEA) 31